Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.

Abstract:

:Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a biologically based personalization of anticancer treatments. In particular, the overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells provided a specific target in these HER2-positive tumors. The development of the monoclonal antibody trastuzumab, and its approval in 1998 for the treatment of patients with metastatic disease, radically changed the natural history of this aggressive subtype of breast cancer. These findings provided strong support for the continuous research in targeting the HER2 pathway and implementing the development of new anti-HER2 targeted agents. Besides trastuzumab, a series of other anti-HER2 agents have been developed and are currently being explored for the treatment of breast cancer patients, including those diagnosed with early-stage disease. Among these agents, neratinib, an oral tyrosine kinase inhibitor that irreversibly inhibits HER1, HER2, and HER4 at the intracellular level, has shown promising results, including when administered to patients previously exposed to trastuzumab-based treatment. This article aims to review the available data on the role of the HER2 pathway in breast cancer and on the different targeted agents that have been studied or are currently under development for the treatment of patients with early-stage HER2-positive disease with a particular focus on neratinib.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Kourie HR,El Rassy E,Clatot F,de Azambuja E,Lambertini M

doi

10.2147/OTT.S122397

subject

Has Abstract

pub_date

2017-07-10 00:00:00

pages

3363-3372

issn

1178-6930

pii

ott-10-3363

journal_volume

10

pub_type

杂志文章,评审
  • Mapping lymph nodes in cancer management - role of (99m)Tc-tilmanocept injection.

    abstract::Two decades ago, lymphatic mapping of sentinel lymph nodes (SLN) was introduced into surgical cancer management and was termed sentinel node navigated surgery. Although this technique is now routinely performed in the management of breast cancer and malignant melanoma, it is still under investigation for use in other ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S50394

    authors: Tausch C,Baege A,Rageth C

    更新日期:2014-06-24 00:00:00

  • H19 Knockdown Suppresses Proliferation and Induces Apoptosis by Regulating miR-130a-3p/SATB1 in Breast Cancer Cells.

    abstract:Purpose:Breast cancer (BC) is the most common cancer in women. Emerging evidence has demonstrated that lncRNAs play an important role in BC. The objective of this study was to investigate the impact of the long non-coding RNA (lncRNA), H19/miRNA-130a-3P/special AT-rich sequence-binding protein-1 (SATB1) axis on BC prog...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S280142

    authors: Zhong G,Lin Y,Wang X,Wang K,Liu J,Wei W

    更新日期:2020-12-07 00:00:00

  • Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study.

    abstract:BACKGROUND:The purpose of this study was to determine the efficacy of sorafenib in preventing and treating tumor recurrence after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria. METHODS:Thirty patients with primary hepatic carcinoma exceeding the Milan criteria underwent ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S31387

    authors: Huang L,Li GM,Zhu JY,Li Z,Li T,Leng XS

    更新日期:2012-01-01 00:00:00

  • MiR-486-5p Act as a Biomarker in Endometrial Carcinoma: Promotes Cell Proliferation, Migration, Invasion by Targeting MARK1.

    abstract:Background:miRNA expression acts as a potential biomarker in many diseases including endometrial carcinoma (EC). miR-486-5p dysregulation is observed in several tumor types, but the roles of miR-486-5p in EC are hardly ever studied. Objective:This study aimed to analyze the expression profile of miR-486-5p in tumor ti...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S246841

    authors: Zheng X,Xu K,Zhu L,Mao M,Zhang F,Cui L

    更新日期:2020-05-28 00:00:00

  • Different setup errors assessed by weekly cone-beam computed tomography on different registration in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.

    abstract::The study aimed to investigate the difference of setup errors on different registration in the treatment of nasopharyngeal carcinoma based on weekly cone-beam computed tomography (CBCT). Thirty nasopharyngeal cancer patients scheduled to undergo intensity-modulated radiotherapy (IMRT) were prospectively enrolled in th...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S87159

    authors: Su J,Chen W,Yang H,Hong J,Zhang Z,Yang G,Li L,Wei R

    更新日期:2015-09-14 00:00:00

  • Genome-Wide Microarray Analysis of circRNAs Revealed Novel Biomarkers for Glioma Treatment and Their Promoting Effect on Glioma Progression.

    abstract:Purpose:As a novel type of non-coding RNAs, circRNAs were found to play important roles in cancer progression. In this study, we aim to investigate genome-wide circRNAs expression and potential functions in glioma to find new therapeutic targets for glioma treatment. Patients and Methods:A total of 92 pairs of glioma ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S241347

    authors: Lyu X,Zhou L,Fan F,Dong Z

    更新日期:2020-04-01 00:00:00

  • Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.

    abstract:Background:Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S159777

    authors: Wang K,Ruan H,Xu T,Liu L,Liu D,Yang H,Zhang X,Chen K

    更新日期:2018-05-28 00:00:00

  • A Phase II prospective nonrandomized trial of magnetic resonance imaging-guided hematopoietic bone marrow-sparing radiotherapy for gastric cancer patients with concurrent chemotherapy.

    abstract:PURPOSE:This study aimed to spare hematopoietical bone marrow (BM) identified by magnetic resonance (MR) radiation in order to alleviate acute hematologic toxicity (HT) for gastric cancer patients treated with postoperative chemoradiotherapy (CRT). METHODS:A prospective, open-label, single-arm Phase II study (Clinical...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S91586

    authors: Wang J,Tian Y,Tang Y,Wang X,Li N,Ren H,Fang H,Feng Y,Wang S,Song Y,Liu Y,Wang W,Li Y,Jin J

    更新日期:2016-05-05 00:00:00

  • Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors.

    abstract::The aim of this study was to investigate the clinical characteristics and efficacy of chronic myeloid leukemia (CML) onset with extreme thrombocytosis. A total of 121 newly diagnosed and untreated CML patients in chronic phase with complete clinical information from the First Hospital of Jilin University, from January...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S142587

    authors: Liu Z,Fan H,Li Y,Liu C

    更新日期:2017-07-17 00:00:00

  • Ribosome Binding Protein 1 Correlates with Prognosis and Cell Proliferation in Bladder Cancer.

    abstract:Introduction:Ribosome binding protein 1 (RRBP1) is reported to be correlated with tumor formation and progression. However, the role of RRBP1 in bladder cancer is unclear. In this study, we aimed to investigate the expression of RRBP1 and its influence on cell proliferation in bladder cancer. Methods:Quantification re...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S252043

    authors: Lv SW,Shi ZG,Wang XH,Zheng PY,Li HB,Han QJ,Li ZJ

    更新日期:2020-07-07 00:00:00

  • Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.

    abstract::Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%-3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the c...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S141053

    authors: Donato EM,Fernández-Zarzoso M,Hueso JA,de la Rubia J

    更新日期:2018-08-06 00:00:00

  • Helicobacter pylori CagA Protein Attenuates 5-Fu Sensitivity of Gastric Cancer Cells Through Upregulating Cellular Glucose Metabolism.

    abstract:Introduction:Gastric cancer (GC) is one of the most malignancies leading to human mortality due to its development, progress, metastasis and poor prognosis, despite the development of remarkable chemotherapy and surgery. The 5-fluorouracil (5-Fu) is an effective anti-gastric cancer agent. However, a fraction of GC patie...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S230875

    authors: Gao S,Song D,Liu Y,Yan H,Chen X

    更新日期:2020-07-01 00:00:00

  • Orbital metastasis as the initial presentation of lung adenocarcinoma: a case report.

    abstract::Orbital metastasis as the initial presentation of lung adenocarcinoma is very rare, and so the lack of knowledge about this phenomenon can easily result in misdiagnosis, either as a orbital primary tumor or benign lesion. Here, we report a rare case in which the orbital symptom appeared first without any pulmonary man...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S99583

    authors: Sun L,Qi Y,Sun X,Yu J,Meng X

    更新日期:2016-05-09 00:00:00

  • Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.

    abstract::In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this setting is poor. A...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S126613

    authors: Fang SC,Zhang HT,Zhang YM,Xie WP

    更新日期:2017-01-18 00:00:00

  • G-MDSCs-Derived Exosomal miRNA-143-3p Promotes Proliferation via Targeting of ITM2B in Lung Cancer.

    abstract:Background:The immune environment of lung cancer is complex, and the critical immune factors that promote lung cancer progression need to be explored. Granulocytic myeloid-derived suppressor cells (G-MDSCs) are regarded as immune suppressing cells. However, they also promote tumor progression through other ways, which ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S256378

    authors: Zhou JH,Yao ZX,Zheng Z,Yang J,Wang R,Fu SJ,Pan XF,Liu ZH,Wu K

    更新日期:2020-09-30 00:00:00

  • Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report.

    abstract::Preclinical studies have demonstrated that Apatinib, major targeting vascular endothelial growth factor receptor-2 (VEGFR-2), could inhibit the proliferation of anaplastic thyroid carcinoma (ATC) cells in vitro and in vivo. The efficacy and safety in ATC patients, however, remains unknown. Here, we report the case of ...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S223727

    authors: Cheng L,Jiao Q,Jin Y,Fu H,Zhang H,Chen L

    更新日期:2019-12-02 00:00:00

  • Urgent Chemotherapy Successfully Rescues a Near Death Patient of Acute Intracranial Hypertension Caused by Intracranial Myeloid Sarcoma.

    abstract::Intracranial myeloid sarcoma is a very rare disease with poor prognosis. We report a case of a 28-year-old male patient who was admitted with intense headache, vision disturbance and severe vomiting in June 2017. He had a history of neurosurgical tumor resection operation in April 2017, and the pathological diagnosis ...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S230478

    authors: Zhou L,Zhang X,Feng S,Zhao N,Hu X,Huang L,Zheng C

    更新日期:2020-01-09 00:00:00

  • MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2.

    abstract:Background:Growing evidence suggests that miR-150 plays an inhibitory role in various types of cancer. However, the function and underlying mechanisms of miR-150 in triple-negative breast cancer (TNBC) remain unknown. Patients and methods:miR-150 expression was detected by qRT-PCR and ISH in TNBC tumor and adjacent no...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S161996

    authors: Tang W,Xu P,Wang H,Niu Z,Zhu D,Lin Q,Tang L,Ren L

    更新日期:2018-04-24 00:00:00

  • Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.

    abstract::The clinicopathological and prognostic significance of telomerase reverse transcriptase (TERT) promoter mutations have been widely investigated in thyroid cancer; however, the results are still discrepant. Systematic searches were performed in PubMed, Web of Science, Scopus, Ovid, and the Cochran Library databases for...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S116594

    authors: Su X,Jiang X,Wang W,Wang H,Xu X,Lin A,Teng X,Wu H,Teng L

    更新日期:2016-11-11 00:00:00

  • Management experiences of primary angiosarcoma of breast: a retrospective study from single institute in the People's Republic of China.

    abstract:BACKGROUND:Primary angiosarcoma of breast (PAOB) is a rare and highly aggressive malignancy. There is no general agreement on optimal treatments or prognostic factors for this orphan disease. The objective of this study was to investigate the clinicopathologic features and management experiences of PAOB. METHODS:We pe...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S92769

    authors: Hu QC,Mei X,Feng Y,Ma JL,Yang ZZ,Shao ZM,Yu XL,Guo XM

    更新日期:2015-11-04 00:00:00

  • The effects and mechanisms of a biosynthetic ginsenoside 3β,12β-Di-O-Glc-PPD on non-small cell lung cancer.

    abstract:Background:A biosynthetic ginsenoside, 3-O-β-D-glucopyranosyl-12-O-β-D-glucopyranosyl-dammar-24-ene-3β, 12β, 20S-triol (C3C12PPD), showed antitumor activity against many tumor cells in vitro, especially had better anti-lung cancer activity than Rg3 in vitro and in vivo. However, the effects and molecular mechanisms of ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S217039

    authors: Huang LL,Tang M,Du QQ,Liu CX,Yan C,Yang JL,Li Y

    更新日期:2019-09-09 00:00:00

  • Long Non-Coding RNA 691 Regulated PTEN/PI3K/AKT Signaling Pathway in Osteosarcoma Through miRNA-9-5p.

    abstract:Background:Large amounts of researches indicate that non-coding RNAs play a crucial role in many malignancies. However, the potential mechanisms of non-coding RNAs involved in osteosarcoma tumorigenesis remain elusive. Materials and Methods:The expression of long non-protein coding RNA 691 (lncRNA 691) in cell lines a...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S249827

    authors: Yao P,Ni Y,Liu C

    更新日期:2020-05-22 00:00:00

  • B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data.

    abstract:Purpose:B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro exper...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S257512

    authors: Yang S,Yuan L,Wang Y,Zhu M,Wang J,Ke X

    更新日期:2020-06-18 00:00:00

  • MicroRNA-188-5p Promotes Epithelial-Mesenchymal Transition by Targeting ID4 Through Wnt/β‑catenin Signaling in Retinoblastoma.

    abstract:Purpose:Here, we investigated the involvement of the miR-188-5p/inhibitor of the DNA binding 4 (ID4) axis in retinoblastoma (Rb). Patients and methods:We included 35 Rb tissues and the corresponding adjacent normal tissues. RT-qPCR, Western blot, lentivirus transfection, measurement of cell migration in vitro, and chi...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S229739

    authors: Yang M,Li Y,Wei W

    更新日期:2019-11-27 00:00:00

  • Comparison of survival rates between 3D conformal radiotherapy and intensity-modulated radiotherapy in patients with stage III non-small cell lung cancer.

    abstract:PURPOSE:Randomized trials showing a clear survival benefit of intensity-modulated radiotherapy (IMRT) over 3-dimensional conformal radiotherapy (3D-CRT) in the treatment of lung cancer are lacking. This study compared the survival rates of patients with stage III non-small cell lung cancer who were treated with either ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S124311

    authors: Kong M,Hong SE

    更新日期:2016-11-24 00:00:00

  • The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy.

    abstract::During the past decade, immunotherapy targeting immune checkpoints has become an important component of the treatment paradigm for numerous malignancies, especially PD-1/PD-L1 blockade which was demonstrated to rejuvenate disabled T cells in cancer patients to achieve long-term remissions. However, the clinical outcom...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S221340

    authors: Cai J,Wang D,Zhang G,Guo X

    更新日期:2019-10-15 00:00:00

  • FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC.

    abstract:Objective:As an epidermal growth factor, receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib demonstrates a good therapeutic effect in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, an overwhelming majority of these patients inevitably develop resistance against gefitinib. Unfortunately, th...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S220462

    authors: Zhang D,Han LL,Du F,Liu XM,Li J,Wang HH,Song MH,Li Z,Li GY

    更新日期:2019-11-18 00:00:00

  • Construction of a recombinant eukaryotic expression vector containing DNM3 gene and its expression in colon cancer cells.

    abstract:Introduction:Dynamin 3 (DNM3) is a large GTPase that possesses mechanochemical properties and has been shown to be involved in malignancies. However, most studies about DNM3 are observational, and knowledge of the precise molecular mechanism of DNM3 remains limited. Materials and methods:We constructed a PCDH-CMV-MCS-...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S176388

    authors: Jiang L,Liang QL,Liang WM,Zhang HJ,Huang J,Yuan GL,Peng XX,Cheng SA,Huang ZG,Zhang XN

    更新日期:2018-10-09 00:00:00

  • miR-218 overexpression suppresses tumorigenesis of papillary thyroid cancer via inactivation of PTEN/PI3K/AKT pathway by targeting Runx2.

    abstract:Background:It was previously reported that downregulation of miR-218 promoted thyroid cancer cell invasion, migration, and proliferation. However, the biological functions of miR-218 and its possible regulatory mechanisms in papillary thyroid cancer (PTC) cells are still elusive. Materials and methods:The expression l...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S172152

    authors: Han M,Chen L,Wang Y

    更新日期:2018-09-28 00:00:00

  • Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma.

    abstract::Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S84153

    authors: Davidson M,Smyth EC,Cunningham D

    更新日期:2016-07-25 00:00:00